Form 4: Palisade Bio Director Binxian Wei Reports Stock Award Vesting

Director Binxian Wei reports the vesting and settlement of restricted stock units into 465 shares of Palisade Bio common stock on June 11, 2024.

Summary

• On June 11, 2024, Binxian Wei, a director of Palisade Bio, Inc., acquired 465 shares of common stock.
• This acquisition resulted from the vesting and settlement of restricted stock units (RSUs) that were granted on June 11, 2023.
• The price per share for the vested RSUs was $0.00.
• Following this transaction, Wei directly owns 467 shares of Palisade Bio common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock vesting, which is a normal part of executive compensation. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The vesting of RSUs indicates that certain performance or time-based milestones have been met.
• Director Wei's increased stake in the company could be seen as a positive sign of confidence in Palisade Bio's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates the vesting of previously granted equity compensation.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Binxian Wei, Palisade Bio, PALI, Restricted Stock Units, RSU, Vesting, Common Stock